South Korea Pharmacovigilance Market Size & Outlook

The pharmacovigilance market in South Korea is expected to reach a projected revenue of US$ 895.9 million by 2030. A compound annual growth rate of 8.8% is expected of South Korea pharmacovigilance market from 2024 to 2030.
Revenue, 2023 (US$M)
$498.0
Forecast, 2030 (US$M)
$895.9
CAGR, 2024 - 2030
8.8%
Report Coverage
South Korea

South Korea pharmacovigilance market highlights

  • The South Korea pharmacovigilance market generated a revenue of USD 498.0 million in 2023 and is expected to reach USD 895.9 million by 2030.
  • The South Korea market is expected to grow at a CAGR of 8.8% from 2024 to 2030.
  • In terms of segment, phase 4 was the largest revenue generating product life cycle in 2023.
  • Phase 1 is the most lucrative product life cycle segment registering the fastest growth during the forecast period.


Pharmacovigilance market data book summary

Market revenue in 2023USD 498.0 million
Market revenue in 2030USD 895.9 million
Growth rate8.8% (CAGR from 2023 to 2030)
Largest segmentPhase 4
Fastest growing segmentPhase 1
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPre Clinical, Phase 1, Phase 2, Phase 3, Phase 4
Key market players worldwideAccenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica


Other key industry trends

  • In terms of revenue, South Korea accounted for 6.8% of the global pharmacovigilance market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China pharmacovigilance market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 340.5 million by 2030.

Phase 4 was the largest segment with a revenue share of 75.64% in 2023. Horizon Databook has segmented the South Korea pharmacovigilance market based on pre clinical, phase 1, phase 2, phase 3, phase 4 covering the revenue growth of each sub-segment from 2018 to 2030.


The market growth can be attributed to the ease of access to pharmaceuticals, rising adoption of polypharmacy, expedited drug development, and rising prevalence of chronic diseases. Moreover, rising government investment in the development of healthcare infrastructure is anticipated to fuel market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pharmacovigilance Market Scope

Pharmacovigilance market segmentation & scope
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
In-house
Contract Outsourcing
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others
Oncology
Neurology
Cardiology
Respiratory Systems
Others
Case Logging
Case Data Analysis
Medical Reviewing & Reporting
Adverse Event Logging
Adverse Event Analysis
Adverse Event Review & Reporting
Risk Evaluation System
Risk Mitigation System

Pharmacovigilance Market Companies

Name Profile # Employees HQ Website

South Korea pharmacovigilance market size, by product life cycle, 2018-2030 (US$M)

South Korea Pharmacovigilance Market Outlook Share, 2023 & 2030 (US$M)

South Korea pharmacovigilance market size, by product life cycle, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more